SCHEMBL23977145

SCHEMBL23977145

O=C1CCCOc2c(F)cccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.44
MAOB P27338 3/20 0.39
CYP2A6 P11509 1/20 0.39
MAOA P21397 1/20 0.39
ACHE P22303 1/20 0.38
ADRA2A P08913 2/20 0.35
PARP1 P09874 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CCNT1 O60563 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
SRD5A1 P18405 1/20 0.33
TYMS P04818 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30029059 1.00 CYP19A1 (0.44) CYP19A1MAOBCYP2A6MAOAACHE
SCHEMBL1265527 0.89 CYP19A1 (0.46) CYP19A1MAOBMAOAADRA2APARP1
SCHEMBL20165370 0.79 MAOB (0.33) MAOBCYP2A6MAOAGRM5
SCHEMBL30779660 0.78 PARP1 (0.54) CYP19A1MAOBMAOAADRA2APARP1
SCHEMBL18331030 0.78 PARP1 (0.54) CYP19A1MAOBMAOAADRA2APARP1
SCHEMBL20165162 0.77 NOTUM (0.39) MAOBCYP2A6MAOAGRM5
SCHEMBL20165267 0.77 PSMB5 (0.44) MAOBCYP2A6MAOAKDM4E
SCHEMBL20179726 0.77 PSMB5 (0.33) MAOBCYP2A6MAOAGRM5
SCHEMBL1181324 0.76 MAPT (0.46) ACHEKDM4ECTNNB1WNT3A
SCHEMBL1812982 0.74 ACHE (0.42) ACHEADRA2APARP1CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 US disclosed
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE HIF1AN, HIF1A, EGLN2 CYP19A1 399/4885MAOB 1081/4885CYP2A6 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.